Oncology Institute Inc [TOI] stock prices are down -3.02% to $4.18 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The TOI shares have gain 13.90% over the last week, with a monthly amount glided 23.67%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Oncology Institute Inc [NASDAQ: TOI] stock has seen the most recent analyst activity on November 25, 2025, when Needham initiated its Buy rating and assigned the stock a price target of $5. Previously, Noble Capital Markets started tracking the stock with Outperform rating on July 23, 2025, and set its price target to $8. On July 16, 2025, B. Riley Securities initiated with a Buy rating and assigned a price target of $6 on the stock. BTIG Research started tracking the stock assigning a Buy rating and suggested a price target of $7 on May 15, 2025. Guggenheim started tracking with a Buy rating for this stock on September 14, 2022, and assigned it a price target of $7. In a note dated August 15, 2022, Jefferies initiated an Buy rating and provided a target price of $10 on this stock.
The stock price of Oncology Institute Inc [TOI] has been fluctuating between $0.25 and $4.88 over the past year. Currently, Wall Street analysts expect the stock to reach $5 within the next 12 months. Oncology Institute Inc [NASDAQ: TOI] shares were valued at $4.18 at the most recent close of the market. An investor can expect a potential return of 19.62% based on the average TOI price forecast.
Analyzing the TOI fundamentals
The Oncology Institute Inc [NASDAQ:TOI] reported sales of 461.04M for trailing twelve months, representing a surge of 36.70%. Gross Profit Margin for this corporation currently stands at 0.15% with Operating Profit Margin at -0.09%, Pretax Profit Margin comes in at -0.14%, and Net Profit Margin reading is -0.14%. To continue investigating profitability, this company’s Return on Assets is posted at -0.41, Equity is 21.04 and Total Capital is -0.42. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-2.23.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Oncology Institute Inc [NASDAQ:TOI]’s Current Ratio is 1.68. On the other hand, the Quick Ratio is 1.39, and the Cash Ratio is 0.42. Considering the valuation of this stock, the price to sales ratio is 0.92.
Transactions by insiders
Recent insider trading involved Carter Robert Ross, Chief Financial Officer, that happened on Jan 02 ’26 when 247.0 shares were sold. Director, Hively Brad completed a deal on Dec 15 ’25 to sell 13333.0 shares. Meanwhile, Director BRADFORD DANIEL HIVELY bought 13333.0 shares on Dec 15 ’25.
